We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    ABTR01B1

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00898079
First Posted: May 12, 2009
Last Update Posted: December 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
May 9, 2009
May 12, 2009
December 13, 2017
March 2003
January 2100   (Final data collection date for primary outcome measure)
Repository of malignant, borderline malignant neoplasms, and related biological specimens [ Time Frame: Baseline ]
Repository of malignant, borderline malignant neoplasms, and related biological specimens
Complete list of historical versions of study NCT00898079 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.

OBJECTIVES:

I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.

II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.

III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.

OUTLINE:

Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
solid tissue (malignant and normal)
Non-Probability Sample
Any patient diagnosed with primary neoplasm, who developed a second malignant neoplasm, any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition.
  • Acute Undifferentiated Leukemia
  • Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
  • Childhood Acute Lymphoblastic Leukemia
  • Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
  • Childhood Chronic Myelogenous Leukemia
  • Chronic Lymphocytic Leukemia
  • Hairy Cell Leukemia
  • Juvenile Myelomonocytic Leukemia
  • Mast Cell Leukemia
  • Neoplasm of Uncertain Malignant Potential
  • Prolymphocytic Leukemia
  • Secondary Acute Myeloid Leukemia
  • T-cell Large Granular Lymphocyte Leukemia
  • Unspecified Childhood Solid Tumor, Protocol Specific
Other: cytology specimen collection procedure
Correlative studies
Other Name: cytologic sampling
Observational
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
Intervention: Other: cytology specimen collection procedure
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
3000
January 2100
January 2100   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets any of the following criteria:

    • Diagnosed with primary neoplasm
    • Developed a second malignant neoplasm
    • Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
  • Must have biological specimens including solid tumors and leukemias available

    • Solid tumors meeting the following criteria:

      • Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)

        • Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
    • Pleural fluid or cytologic specimens meeting the following criteria:

      • At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)

        • Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
    • ALL/AML

      • 3-6 mL of bone marrow aspirate and 10 mL of whole blood
  • Not eligible for disease-specific biology or banking protocol
Sexes Eligible for Study: All
up to 30 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   New Zealand,   Puerto Rico,   Switzerland,   United States
 
 
NCT00898079
ABTR01B1
NCI-2009-00324 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
COG-ABTR01B1 ( Other Identifier: Children's Oncology Group )
ABTR01B1 ( Other Identifier: Children's Oncology Group )
ABTR01B1 ( Other Identifier: CTEP )
U10CA098543 ( U.S. NIH Grant/Contract )
No
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Nilsa Ramirez, MD Children's Oncology Group
Children's Oncology Group
December 2017